7
Registered trials
2
Recruiting
4
Unique sponsors
4
Unique IMPs
7
Commercial trials
Drug classes (ATC)
—
ATC code not specified
5
N
Neurology/Psychiatry (ATC N)
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
4 substances
Phase III:
2
Phase II:
3
Phase I (First in Human):
2
Phase III
2 trials-
RecruitingAvidity Biosciences Inc. CommercialHUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TFR1 CONJUGATED TO DOUBLE STRANDED SIRNA OLIGONUCLEOTIDE AGAINST DUX4 MRNA VIA A NON-CLEAVABLE LINKER
-
EndedFulcrum Therapeutics Inc. CommercialLOSMAPIMOD
Phase II
3 trials-
EndedF. Hoffmann-La Roche AG CommercialHUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN LATENT MYOSTATIN
-
EndedFulcrum Therapeutics Inc. CommercialLOSMAPIMOD
-
EndedFulcrum Therapeutics Inc. CommercialLOSMAPIMOD
Phase I (First in Human)
2 trials-
EndedAvidity Biosciences Inc. CommercialHUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TFR1 CONJUGATED TO DOUBLE STRANDED SIRNA OLIGONUCLEOTIDE AGAINST DUX4 MRNA VIA A NON-CLEAVABLE LINKER
-
RecruitingSarepta Therapeutics Inc. CommercialADS-010
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Fulcrum Therapeutics Inc. | Commercial | 3 | Phase II, Phase III | 0 |
| Avidity Biosciences Inc. | Commercial | 2 | Phase III, Phase I (First in Human) | 1 |
| F. Hoffmann-La Roche AG | Commercial | 1 | Phase II | 0 |
| Sarepta Therapeutics Inc. | Commercial | 1 | Phase I (First in Human) | 1 |
New trials by year
2019
2
2022
2
2025
1
2026
1